

# **LIVER AND RHEUMATIC DISEASES**

**Essay**

*Submitted for Partial Fulfillment of Master Degree  
in Internal Medicine*

*By*

**Shimaa Farouk Ahmed Kenawy**

*M.B.B.ch.*

*Ain Shams University*

*Under Supervision of*

Prof. Dr. Dahlia Abdel Mohsen  
Hussein

*Professor of Internal Medicine and Rheumatology  
Faculty of Medicine -Ain Shams University*

Prof. Dr. Eman Ahmad Hafez  
*Professor of Internal Medicine and Rheumatology  
Faculty of Medicine -Ain Shams University*

Dr. Reem Abdel Moniem Mohamed  
*Lecturer of Internal Medicine and Rheumatology  
Faculty of Medicine -Ain Shams University*

**Ain Shams University**  
**2010**

## *Acknowledgement*

*First and foremost I feel always indebted to ALLAH, the Most Beneficent and Merciful*

*I would first like to express my unlimited gratitude and thankfulness to my Prof. Dr. Dahlia Abdel Mohsen Hussein, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for her acceptance to supervise my work and for her continuous support, her valuable advises and encouragement without her encourage and help I would not have been able to finish this work,*

*Many thanks to Dr. Eman Ahmad Hafez, Professor of Internal Medicine, Ain Shams University, who showed me the way and the first steps for going on into this work, who helped me much and her continuous guidance.*

*My deepest gratitude and appreciation are to Dr. Reem Abdel Moniem Mohamed, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her generous help and valuable comments during the preparation of this work*

# List of Contents

	<i>Page</i>
<b>Introduction and Aim of the Work .....</b>	<b>1</b>
<b>Chapter (1): Hepatic manifestations in rheumatic diseases .....</b>	<b>5</b>
<b>Chapter (2): Rheumatic manifestations in Hepatic diseases .....</b>	<b>62</b>
<b>Chapter (3): Safety and monitoring of common drugs used in rheumatic diseases as regard hepatic affection .....</b>	<b>123</b>
<b>Summary and Recommendations .....</b>	<b>157</b>
<b>References .....</b>	<b>160</b>
<b>Arabic Summary .....</b>	<b>—</b>

## List of Figures

<i><b>Figure</b></i>	<i><b>Page</b></i>
<b>Figure (1):</b> Liver acinus: hepatic lobules are represented by hexagons (solid lines); liver acinus is represented by rhombus (dotted line) .....	6
<b>Figure (2):</b> Diagram of liver hepatocyte organization in a lobule .....	7
<b>Figure (3):</b> Congo-red–stained section for amyloidosis .....	17
<b>Figure (4):</b> Structure of the hepatitis B virus .....	62
<b>Figure (5):</b> Structure of Hepatitis C virus .....	71
<b>Figure (6):</b> Nodular regenerative hyperplasia of the liver .....	101
<b>Figure (7):</b> Liver biopsy revealing autoimmune hepatitis: Acute hepatitis with lymphoplasmacytic infiltrate in the portal and periportal interface, extending into the parenchyma .....	105

## List of Tables

<i>Tables</i>	<i>Page</i>
<b>Table (1):</b> American Rheumatism Association Criteria for the Classification of Rheumatoid Arthritis .....	11
<b>Table (2):</b> The revised criteria for the diagnosis of systemic lupus erythematosus .....	27
<b>Table (3):</b> Main associations of liver disease in rheumatic autoimmune disease .....	61
<b>Table (4):</b> Different degrees of association between hepatitis C virus and systemic autoimmune diseases .....	77
<b>Table (5):</b> Major forms of hepatic abnormalities recorded in patients with rheumatic diseases .....	122
<b>Table (6):</b> Revised guidelines for Monitoring of liver toxicity in patients treated with methotrexate of the American Academy of Dermatology .....	130
<b>Table (7):</b> Summary of Monitoring of MTX in case of psoriasis and Rheumatoid arthritis .....	131

<b>Table (8):</b>	Action to be taken in case of transaminases abnormalities .....	136
<b>Table (9):</b>	Baseline laboratory monitoring for disease modifying anti-rehumatic drugs .....	150
<b>Table (10):</b>	Tocilizumab adjustment in case of liver tansaminases abnormalties .....	152

## List of Abbreviations

<b>γGT</b> .....	Gamma glutamyl transferase
<b>aCL</b> .....	Anticardiolipin antibodies
<b>ACR</b> .....	American College of Rheumatology
<b>AIH</b> .....	Autoimmune hepatitis
<b>ALP</b> .....	Alkaline phosphatase
<b>ANA</b> .....	Antinuclear antibody
<b>aPL</b> .....	Antiphospholipid antibodies
<b>AZA</b> .....	Azathioprine
<b>CYP</b> .....	Cyclophosphamide
<b>CSA</b> .....	Cyclosporine
<b>CXR</b> .....	Chest radiograph
<b>DEXA</b> .....	Dual-energy x-ray absorptiometry
<b>DMARDS</b> ..	Disease modifying antirheumatic drugs
<b>EHM</b> .....	Extrahepatic manifestations
<b>ENA</b> .....	Extractable nuclear antigen
<b>FBC</b> .....	Full blood count
<b>HBV</b> .....	Hepatitis B virus
<b>HCC</b> .....	Hepatocellular carcinoma



**HCV** .....Hepatitis C virus  
**HIV** .....Human immunodeficiency virus  
**HPS** .....Hemophagocytic syndrome  
**IFN** .....Interferon  
**LEF** .....Leflunomide  
**LFT** .....Liver function test  
**MTX** .....Methotrexate  
**NRH** .....Nodular regenerative hyperplasia  
**NSAID** .....Non steroidal anti-inflammatory drugs  
**P3NP** .....Procollagen III amino terminal peptide  
**PAN** .....Polyarteritis nodosa  
**PBC** .....Primary biliary cirrhosis  
**RA** .....Rheumatoid arthritis  
**RF** .....Rheumatoid factor  
**SLE** .....Systemic lupus erythematosus  
**SS** .....Sjögern's syndrome  
**SSc** .....Systemic sclerosis  
**TCZ** .....Tocilizumab  
**TNFa** .....Tumor necrosis factor  
**WBC** .....White blood cell count

## **Introduction**

The liver is the largest gland in the body weighing 1500 gm with many complex functions. These functions of the liver allow the body maintenance of homeostasis. A wide variety of rheumatic diseases affect the liver and their prevalence, significance and specific hepatic pathology varies with each disease (*Abraham et al., 2004*). Also rheumatic features are common in liver diseases (*Albert et al., 2007*).

Rheumatoid arthritis causes extra articular manifestations which are rare and exceptionally serious in the liver. The most important hepatic disorders associated with rheumatoid arthritis are intrahepatic portal hypertension without cirrhosis, amyloidosis and drug hepato-toxicity (*Diouf et al., 2001*).

Nodular Regenerative hyperplasia (NRH) is made of diffuse nodules of hepatocytes without fibrosis and it is closely associated with felty's syndrome (*Diouf et al., 2001*).

Although symptomatic liver involvement is rare in Sjögren's Syndrome (SS), asymptomatic liver involvement is common in the form of primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), hepatitis C virus (HCV) infection and fatty liver. Clinicians must be aware of the possibility of liver involvement so that it can be treated as soon as possible (*Aoki et al., 2004*).

Systemic lupus erythematosus (SLE) is an immune mediated systemic disease associated with diverse abnormalities of the skin, kidneys, hematological and musculoskeletal systems. Abnormalities of the liver function are not included in the diagnostic criteria of SLE, and the liver is generally not regarded as a major target organ for damage in patients with SLE (*Lu et al., 2006*). However hepatic disease may be more common in systemic lupus erythematosus (SLE) than is usually thought (*Abraham et al., 2004*).

There is no characteristic histological feature present in the liver of patients with SLE. A variety of histological lesions have been observed on liver biopsy in patients with SLE including cholestasis with prominent bile plugs, steatosis, acute or chronic hepatitis and cirrhosis. A form of cholestasis described as canalicular cast of bile was reported to be peculiar to SLE patients with liver disease (*Chow et al., 1997*).

As regard extrahepatic manifestations of liver diseases there are many rheumatological manifestations associated with chronic hepatitis C virus (HCV) infection including arthralgia, myalgia, arthritis, vasculitis and sicca syndrome. The picture may mimic rheumatoid arthritis (RA), particularly as rheumatoid factor is present in 50- 80 % of cases, also sicca syndrome is common in patients with chronic HCV infection and shares similarities with primary sjögren syndrome (*Lormeau et al., 2006*).

Primary biliary cirrhosis (PBC) is often associated with other non - hepatic autoimmune diseases, especially primary sjögren's syndrome, which may favour articular involvement. PBC and rheumatoid arthritis (RA) have been suggested to coexist in 1.8 to 5.6% of patients with PBC (*Caramella et al., 2007*).

Autoimmune hepatitis has clinical manifestations, serological markers, pathogenic mechanisms, genetic predispositions and therapies similar to the rheumatic diseases. The rheumatic manifestations may mask the underlying liver disease and vice versa (*Czaja, 2007*).

## **Aim of the Work**


The aim of this work is to review recent studies that clarify the hepatic involvement in rheumatic diseases as well as the rheumatic manifestations of hepatic diseases.

## **Hepatic Manifestations in Rheumatic Diseases**

### **Liver Structure and Function**

The liver is the largest organ of the body, weighing 1 to 1.5 kg and representing 1.5 to 2.5% of the lean body mass. The size and shape of the liver vary and generally match the general body shape, long and lean or squat and square. The liver is located in the right upper quadrant of the abdomen under the right lower rib cage against the diaphragm and projects for a variable extent into the left upper quadrant (*Ghany and Hoofnagle, 2005*).

The liver is held in place by ligamentous attachments to the diaphragm, peritoneum, great vessels and upper gastrointestinal organs. It receives a dual blood supply; approximately 20% of the blood flow is oxygen-rich blood from the hepatic artery and 80% is nutrient-rich blood from the portal vein arising from the stomach, intestines, pancreas and spleen (*Ghany and Hoofnagle, 2005*).



**Figure (1):** Liver acinus: hepatic lobules are represented by hexagons (solid lines); liver acinus is represented by rhombus (dotted line).

[www.medical-dictionary.thefreedictionary.com](http://www.medical-dictionary.thefreedictionary.com)

The majority of cells in the liver are hepatocytes, which constitute two third of the mass of the liver. The remaining cell types are Kupffer cells (members of the reticuloendothelial system), stellate (Ito or fat-storing) cells, endothelial cells and blood vessels, bile ductular cells and supporting structures. Viewed by light microscopy, the liver appears to be organized in lobules, with portal areas at the periphery and central veins in the center of each lobule. However, from a functional point of view, the liver is organized into acini, with both hepatic arterial and portal venous blood entering the acinus from the portal areas (zone 1) and then flowing through the sinusoids to the terminal of hepatic veins (zone 3); the intervening hepatocytes